# Study of RP-3500 (Camonsertib) With Niraparib or Olaparib in Advanced Solid Tumors

> **NCT04972110** · PHASE1,PHASE2 · TERMINATED · sponsor: **Repare Therapeutics** · enrollment: 156 (actual)

## Conditions studied

- Advanced Solid Tumor, Adult

## Interventions

- **DRUG:** RP-3500 (camonsertib)

## Key facts

- **NCT ID:** NCT04972110
- **Lead sponsor:** Repare Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-07-21
- **Primary completion:** 2024-11-13
- **Final completion:** 2024-11-13
- **Target enrollment:** 156 (ACTUAL)
- **Why stopped:** Sponsor decided to terminate study early therefore, the Phase 2 portion was not conducted
- **Last updated:** 2025-10-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04972110

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04972110, "Study of RP-3500 (Camonsertib) With Niraparib or Olaparib in Advanced Solid Tumors". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT04972110. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*